Inhibiting ATG4D may impair the autophagic process that allows NPC cells to thrive, particularly in the presence of EBV, potentially leading to increased sensitivity to chemotherapy and radiotherapy. This evidence concerns the gene ATG4D and nasopharyngeal carcinoma.